Eric Neyret, General Manager for Finance & Administration
MEDICE Whether as patient, doctor, pharmacist or employee – with us the individual person is always the focus of attention.
Eric Neyret, General Manager for Finance & Administration
You are here: Home / The Company / Our business units

Our business units

You can always expect one thing from us: only the best.

MEDICE (company description):

MEDICE ranks number 3 among family-owned pharmaceutical companies in Germany with own manufacturing, development, logistics and marketing nationally and internationally in more than 50 countries, through own subsidiaries or long-term partnerships. Committed to the fundamental ethical values of medicine, with 3 physicians in general management, MEDICE has been demonstrating for 65 years that long-term orientation and risk diversification are our strong basis for innovation and sustainable growth. Thus, we are pursuing leading positions in specialized areas of competence:

 

Central nervous system / attention deficit hyperactivity disorder (ADHD)

With Medikinet® (short-acting methylphenidate) and Medikinet® XL (modified release methylphenidate with 8 hours duration of action) associated with relevant diagnostic and therapeutic services presented to specialists for 15 years we have achieved more than 44% of prescriptions indicated for pharmacotherapy of ADHD in children and adolescents in Germany and 25% in Europe. In addition, we have launched as second line medication the first dexamphetamine product in Europe in 2011. Also in 2011, we were first in getting approval for Medikinet adult®, our proprietary formulation of methylphenidate indicated for adults with ADHD.

Renal Care / Nephrology

MEDICE offers a wide range of products, services and preparations indicated for patients with chronic kidney disease (CKD I-V, dialysis): Abseamed®, the first biosimilar epoetin approved by EMA, FerMed® and Monofer® as innovative parenteral iron products; Nephrotrans® our proprietary sustained release formulation of hydrogenbicarbonate indicated for metabolic acidosis, Antipotassium® against hyperkalemia. Additonally, we hold a market leading position in CKD-MBD and phosphate management with vitamin D derivatives, calcium and non-calcium based products: Calciumacetate, Calciumcarbonate, Aluminiumhydrochlorid, Sevelamer and proprietary modified release nicotinamide NOPHOS.

General Medicine (RX, 2°market) and consumer health (OTC)

Proven efficacy with medical benefit and safety profile are always at the forefront our products; in consumer health brand awareness is also crucial. Consequently, we aim at being in the relevant set of general practitioners and end consumers:

Our leading brands at the pharmacy level are Meditonsin® and Doregrippin® against common cold, Dorithricin® against sore throat, Soventol® indicated for skin lesions, Perenterol®, Santalyt® and Tannacomp® against diarrhea.

Prescription based Circadin® modified melatonin promotes healthy sleep, can be taken long-term without any risk of addiction, Medivitan® is considered the re-vitalizing injection with a strong evidence base (Lancet, 1995).